Adrian JohnsonTLDR:
- PetMed Express disclosed preliminary Q3 results, including an 11% sales increase, and a planned restatement due to accounting errors.
- The restatement is primarily due to errors in accounting for tax-related matters and is estimated to have a sales tax liability of approximately $14 to $20 million.
- Despite the restatement, PetMed Express remains committed to growth and innovation, launching new products and services, and addressing challenges.
- The company highlighted operational advancements during the quarter, such as the launch of a new AutoShip platform and the addition of Hill’s Science Diet to its product offerings.
- PetMed Express, Inc. is optimistic about its future, with a strong cash position, expanding product offerings, and a loyal customer base.
PetMed Express, the leading provider of pet healthcare products, has disclosed its preliminary financial results for the third quarter, along with an unexpected announcement of a planned restatement of certain previously issued financial statements. The restatement is primarily due to errors in accounting for tax-related matters, including miscalculations in sales tax accruals and the valuation of a deferred tax asset associated with the acquisition of PetCareRx. The estimated sales tax liability is approximately $14 to $20 million. Despite the restatement, PetMed Express reassured stakeholders that it will not impact fiscal 2024 revenue, cost of sales, current cash balance, day-to-day operations, or strategic priorities.
The company highlighted significant operational advancements during the quarter, such as the launch of a new AutoShip platform and the addition of Hill’s Science Diet to its product offerings. These strategic moves have not only expanded the company’s product portfolio but also strengthened its position in the competitive pet healthcare market.
CFO Christine Chambers shared insights into the impacts of the planned restatement and the preliminary third-quarter results. Despite the restatement, the company reported a gross margin of 27.4% and returning customers accounting for $57.7 million in sales. PetMed Express remains focused on its strategic initiatives, including the introduction of a premium food brand and enhancements to its recurring revenue streams through the AutoShip Save and PetPlus programs.
While the restatement may delay the filing of its Quarterly Report on Form 10-Q for the quarter ended December 31, 2023, PetMed Express Inc is optimistic about its future. With a strong cash position, expanding product offerings, and a loyal customer base, the company is well-positioned to navigate the challenges ahead and continue its mission of providing exceptional pet healthcare products and services.
